Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery (COMPASS)
This study is currently recruiting participants.
Verified July 2012 by Transcend Medical, Inc.
Sponsor:
Transcend Medical, Inc.
Information provided by (Responsible Party):
Transcend Medical, Inc.
ClinicalTrials.gov Identifier:
NCT01085357
First received: March 1, 2010
Last updated: July 3, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is to evaluate the safety and efficacy of the CyPass Implant for lowering intraocular pressure in patients with glaucoma who undergo cataract surgery.
| Condition | Intervention |
|---|---|
|
Primary Open Angle Glaucoma (POAG) Cataract |
Procedure: Cataract Surgery Device: CyPass Micro-stent |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Prospective, Randomized, Comparative, MultiCenter Clinical Study to Assess the Safety and Effectiveness of the Transcend CyPass Glaucoma Implant in Patients With Open Angle Glaucoma Undergoing Cataract Surgery |
Resource links provided by NLM:
Further study details as provided by Transcend Medical, Inc.:
Primary Outcome Measures:
- Proportion of eyes with ≥ 20% decrease in intraocular pressure (IOP) from baseline to the hypotensive medication-free 24-month postoperative examination [ Time Frame: 24 months postoperative ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Mean change in IOP between baseline and hypotensive medication-free 24-month postoperative examination [ Time Frame: 24 months postoperative ] [ Designated as safety issue: No ]
- Proportion of eyes with postoperative IOP ≥ 6 and ≤ 18 mmHg, as measured by Goldmann Tonometry, at the hypotensive medication-free 24-month postoperative examination [ Time Frame: 24 months postoperative ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 723 |
| Study Start Date: | September 2009 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: CyPass + Cataract Surgery
Subjects in the CyPass + Cataract Surgery arm of the study will receive the CyPass implant at the conclusion of their cataract surgery.
|
Device: CyPass Micro-stent
The CyPass Micro-stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye.
|
|
Active Comparator: Cataract Surgery
Subjects in the Cataract Surgery arm of the study will not receive the CyPass implant at the conclusion of their cataract surgery.
|
Procedure: Cataract Surgery
Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artifical lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
|
Eligibility| Ages Eligible for Study: | 45 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Preoperative Inclusion Criteria:
- Diagnosis of primary open angle glaucoma (POAG)
- Mean diurnal unmedicated IOP of 21 - 33 mmHg
- Normal anterior chamber angle anatomy at site of implantation
- Operable age-related cataract
Exclusion Criteria:
- Use of more than 3 ocular hypotensive medications (combination medications count as 2 medications)
- Significant risk associated with washout of ocular hypotensive medication
- Previous glaucoma surgery (with exception of laser treatments to the trabecular meshwork)
- Previous corneal surgery
- Clinically significant ocular pathology, other than cataract and glaucoma
- Diagnosis of acute angle closure, traumatic, congenital, malignant, uveitic, pseudoexfoliative, pigmentary or neovascular glaucoma
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01085357
Show 23 Study Locations
Contacts
| Contact: Ginger Clasby | 949-379-1962 ext 206 | |
| Contact: Marina Ciccone | 949-379-1962 ext 204 |
Show 23 Study LocationsSponsors and Collaborators
Transcend Medical, Inc.
More Information
Additional Information:
No publications provided
| Responsible Party: | Transcend Medical, Inc. |
| ClinicalTrials.gov Identifier: | NCT01085357 History of Changes |
| Other Study ID Numbers: | TMI-09-01 |
| Study First Received: | March 1, 2010 |
| Last Updated: | July 3, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Transcend Medical, Inc.:
|
Glaucoma Glaucoma device Glaucoma surgery Intraocular pressure |
Additional relevant MeSH terms:
|
Glaucoma Glaucoma, Open-Angle Cataract |
Ocular Hypertension Eye Diseases Lens Diseases |
ClinicalTrials.gov processed this record on May 16, 2013